scout

Authors

Walter Alexander
Latest Article

Third-Line Eribulin Effective, Safe in Metastatic Breast Cancer

Among patients with HER2-negative stage IIIb/IV breast cancer who have progressed after a taxane or anthracycline therapy, a multicenter single-arm study of third-line eribulin demonstrated both safety and efficacy.

Walter J. Curran Jr, MD
Walter J. Curran, Jr., MD, FACR
Latest Article

Radiation Therapy Dose for the Treatment of Patients With Lung Cancer

Walter J. Curran, Jr., MD, FACR, associate vice president of cancer, Woodruff Health Sciences Center, executive director, Winship Cancer Institute, Lawrence W. Davis Chair of Radiation Oncology, Emory University, discusses radiation therapy dose for the treatment of patients with lung cancer.

Wayne Kuznar
Latest Article

BGB-11417 +/- Zanubrutinib Demonstrates Early Efficacy Signals in CLL/SLL

Phase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.

Wayne Kuzner
Latest Article

PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer

With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.

Wells Messersmith, MD
Will Pass, DVM
Latest Article

FDA Issues Draft Guidance to Broaden Clinical Trial Inclusion

The FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.

William M. Grady, MD
William Oh, MD
Latest Article

Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study

Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.

William T. DeRosa, DO
William Wierda, MD, PhD
Wilson I. Gonsalves, MD
Xiaoliang Wu, MD
Latest Article

Current Role of MET Inhibitors in Cancer Therapy

Emerging discoveries of MET chromosomal fusions provide additional promise as therapeutic genomic targets in MET cancer therapy and would need to be tested vigorously.

Yujie Zhao, MD, PhD
Latest Article

Levantinib in the Management of Differentiated Thyroid Cancer

Therapy that targets angiogenesis has been extensively investigated in differentiated thyroid cancer (DTC) and has demonstrated significant antitumor activity.

Zachary S. Buchwald, MD, PhD
Gina Mauro
Latest Article

High-Risk Features Linked to Early Progression on Epcoritamab/Glofitamab

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

Nina Shah, MD

Nina Shah, MD, is a hematologist-oncologist at University of California, San Francisco who focuses on treating multiple myeloma.

Richard Payerchin
Latest Article

Nine Staff Management Essentials for Physicians

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and improving patient care.

Ian E. Krop, MD, PhD
Marielle Fares, PharmD, BCGP
Latest Article

Novel Delivery Systems, Unique Pairings Explored With Oncolytic Viruses

Oncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.

Ashok Muthukrishnan, MD, MS
Ashok Muthukrishnan, MD, MS

Ashok Muthukrishnan, MD, MS, is the chief of Nuclear Medicine, and director of Theranostics in the Department of Radiology at the University of Pittsburgh Medical Center in Pittsburgh, PA.

Latest Article

Pluvicto Approval Launches Theranostics in Prostate Cancer

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

Niroshana Anandasabapathy, MD, PhD
Latest Article

Melanoma Monday: From Early Detection to Cutting-Edge Treatments

May 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against melanoma.

Peter Hillmen, MBChB, PhD
Latest Article

Hillmen Analyzes Current and Upcoming Trials of BTK Inhibitors

During a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.

Moneeza Walji, MD, MPH
Latest Article

Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid Leukemia

Allogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.

Antonia DePace
Latest Article

Improved Communication Needed for Patients Living with Renal Cell Carcinoma

A lack of understanding about renal cell carcinoma (RCC), clinical trials, and the diseases psychosocial impact may exist in patients living with the illness and their families.

Spencer Feldman
Latest Article

Acupuncture Shows Lasting Cognitive Benefits for Cancer Survivors

Real acupuncture significantly enhances cognitive health in breast cancer survivors, outperforming usual care and showing promise over sham treatments.

James Valeriano, MD
Kota Kubo
Latest Article

How Self-Monitoring and Data Sharing Produce Better Patient Outcomes

More than half of all patients do not remember their physicians’ recommendations and treatments unless prompted.

Tomislav Dragovich, MD, PhD
Latest Article

20 Years of Trials, Hope and Progress for Patients with Pancreatic Adenocarcinoma

In a comprehensive review of the last 20 years of advancements and challenges in the pancreatic adenocarcinoma landscape, Dr. Tomsilav Dragovich highlights how treatment has evolved for this patient population.

Kaci Treasure

Kaci Treasure is a summer 2023 intern at Targeted OncologyTM.

Latest Article

TIL Quantity Greatly Impacts Survival in Metastatic Breast Cancer

In an interview with Targeted Oncology, Daniel G. Stover, MD, highlighted the objective to enhance delivery of endocrine therapy plus CDK4/6 inhibitors to patients with hormone receptor-positive, HER2-negative breast cancer by utilizing biomarker assessments as a guide to interchange or cease treatment at the most favorable time.